Cargando…

Interactions between Medical Residents and Drug Companies: A National Survey after the Mediator® Affair

BACKGROUND: The present study aimed to describe exposure and attitudes of French medical residents towards pharmaceutical industry. The study was performed shortly after the Mediator affair which revealed several serious conflicts of interest inside the French health system. METHODS AND FINDINGS: A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Montastruc, François, Moulis, Guillaume, Palmaro, Aurore, Gardette, Virginie, Durrieu, Geneviève, Montastruc, Jean-Louis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184806/ https://www.ncbi.nlm.nih.gov/pubmed/25279555 http://dx.doi.org/10.1371/journal.pone.0104828

Ejemplares similares

Serious adverse drug reactions with hydroxychloroquine: a pharmacovigilance study in Vigibase®
por: Montastruc, Jean-Louis, et al.
Publicado: (2020)

Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019
por: Montastruc, François, et al.
Publicado: (2020)

COVID-19 vaccines: A perspective from social pharmacology
por: Montastruc, Jean-Louis, et al.
Publicado: (2021)

Cancer Risk of Anti-TNF-α at Recommended Doses in Adult Rheumatoid Arthritis: A Meta-Analysis with Intention to Treat and per Protocol Analyses
por: Moulis, Guillaume, et al.
Publicado: (2012)

A New Drug–Drug Interaction Between Hydroxychloroquine and Metformin? A Signal Detection Study
por: Montastruc, Jean-Louis, et al.
Publicado: (2020)

Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns
por: Touafchia, Anthony, et al.
Publicado: (2021)

Adverse drug reactions and ivermectin in COVID-19
por: Montastruc, Jean-Louis
Publicado: (2022)

Corticosteroid Risk Function of Severe Infection in Primary Immune Thrombocytopenia Adults. A Nationwide Nested Case-Control Study
por: Moulis, Guillaume, et al.
Publicado: (2015)

Cross-national health care database utilization between Spain and France: results from the EPICHRONIC study assessing the prevalence of type 2 diabetes mellitus
por: Moulis, Guillaume, et al.
Publicado: (2018)

Drug–drug interactions with imatinib: An observational study
por: Récoché, Isabelle, et al.
Publicado: (2016)

Hypertension and Covid-19 vaccines: are there any differences between the different vaccines? A safety signal
por: Bouhanick, Beatrice, et al.
Publicado: (2021)

Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database
por: Berthet, Stephanie, et al.
Publicado: (2011)

Pharmacological characteristics of patients infected with SARS-Cov-2 admitted to Intensive Care Unit in South of France
por: Montastruc, François, et al.
Publicado: (2020)

Quality of reporting of adverse events in clinical trials of covid-19 drugs: systematic review
por: Madi, Karima, et al.
Publicado: (2023)

Perception of teratogenic and foetotoxic risk by health professionals: a survey in Midi-Pyrenees area
por: Damase-Michel, Christine, et al.
Publicado: (2008)

French pharmacovigilance survey of casirivimab - imdevimab monoclonal antibodies in coronavirus disease (COVID-19)
por: de Canecaude, Claire, et al.
Publicado: (2023)

Case Report: A Case of Valproic Acid-Induced Hyperammonemic Encephalopathy Associated With the Initiation of Lithium: A Re-duplicable Finding
por: Levy, Anna, et al.
Publicado: (2022)

Medical Affairs in Pharmaceutical Companies and Related Pharmaceutical Regulations in Japan
por: Maeda, Hideki
Publicado: (2021)

Laboratory Monitoring of Patients Treated with Antihypertensive Drugs and Newly Exposed to Non Steroidal Anti-Inflammatory Drugs: A Cohort Study
por: Fournier, Jean-Pascal, et al.
Publicado: (2012)

Increased reporting of venous and arterial thromboembolic events reported with tixagevimab–cilgavimab for coronavirus disease 2019
por: Montastruc, François, et al.
Publicado: (2023)

Kidney disorders as serious adverse drug reactions of remdesivir in coronavirus disease 2019: a retrospective case–noncase study
por: Chouchana, Laurent, et al.
Publicado: (2021)

Oxford-AstraZeneca COVID-19 vaccine-induced cerebral venous thrombosis and thrombocytopaenia: A missed opportunity for a rapid return of experience
por: Geeraerts, Thomas, et al.
Publicado: (2021)

The Cost of Potentially Inappropriate Medications in Nursing Homes in West Occitanie
por: Caucat, Marie, et al.
Publicado: (2020)

Cognitive, functional, physical, and nutritional status of the oldest old encountered in primary care: a systematic review
por: Escourrou, Emile, et al.
Publicado: (2020)

Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study
por: Garcia, Philippe, et al.
Publicado: (2020)

Evaluation of off-service rotations at National Guard Health Affairs: Results from a perception survey of off-service residents
por: Alquraini, Mustafa M., et al.
Publicado: (2013)

Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial
por: Defer, Gilles, et al.
Publicado: (2018)

The Hospital Spirit in National Affairs
Publicado: (1916)

French Pharmacovigilance Public System and COVID-19 Pandemic
por: Grandvuillemin, Aurélie, et al.
Publicado: (2020)

Serious Neurological Adverse Events of Ceftriaxone
por: Lacroix, Clémence, et al.
Publicado: (2021)

Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study
por: Abrahami, Devin, et al.
Publicado: (2018)

The National Publishing Company
Publicado: (1867)

Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?
por: Concordet, Didier, et al.
Publicado: (2019)

How to deprescribe esketamine in resistant depression? A point of view after first clinical uses
por: Taillefer de Laportalière, T., et al.
Publicado: (2022)

Authors’ Reply to Castello-Bridoux et al.: “Comment on Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?”
por: Concordet, Didier, et al.
Publicado: (2019)

Authors’ Reply to Nicolas: “Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?”
por: Concordet, Didier, et al.
Publicado: (2019)

Authors’ Reply to Coste et al.: “Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?”
por: Concordet, Didier, et al.
Publicado: (2019)

Authors’ Reply to Lechat et al.: “Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?”
por: Concordet, Didier, et al.
Publicado: (2019)

Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?
por: Concordet, Didier, et al.
Publicado: (2019)

Authors’ Reply to Nicolas: “Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
por: Concordet, Didier, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fbn45lpnkss2cctig16s2je35m